Observational studyBMC musculoskeletal disorders2026
Efficacy and safety of rivaroxaban versus low-molecular-weight heparin for the prevention of symptomatic in-hospital venous thrombosis following primary total hip and knee arthroplasty: a large-sample, multicenter, retrospective study.
Observational study in BMC musculoskeletal disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeTo evaluate the efficacy and safety of rivaroxaban and low molecular weight heparin (LMWH) for the prevention of postoperative venous thrombosis (VTE) following primary unilateral total hip arthroplasty (THA) and total knee arthroplasty (TKA).
methodsA total of 11,686 patients who received rivaroxaban and LMWH (6,110 cases of THA and 5,576 cases of TKA) between January 2014 and November 2017 in 26 large teaching hospitals were enrolled. The patients were divided into two groups according to the postoperative use of anticoagulant drugs, including 4,591 cases in the rivaroxaban group (2,288 cases of THA and 2,303 cases of TKA) and 7,095 cases in the LMWH group (3,822 cases of THA and 3,273 cases of TKA). The incidence of deep vein thrombosis (DVT) in the lower extremities, and pulmonary embolism (PE), were analyzed as indicators of efficacy. The incidences of postoperative bleeding events, total blood loss (TBL), and transfusion rate, were considered as safety indicators.
resultsThe overall incidence of DVT was 0.40% (47/11,686) in patients undergoing primary THA/TKA. The incidence of DVT in the rivaroxaban group was 0.74% (34/4591); this was significantly higher than that in the LMWH group (0.18%; 13/7095) (OR 4.07, 95% CI 2.14-7.71;p < 0.001). In the THA subgroup, the incidence of DVT in the rivaroxaban group was 0.52% (12/2288 cases); this was significantly higher than that in the LMWH group 0.10% (0.10%; 4/3822) (p = 0.002). In the TKA subgroup, the incidence of DVT was 0.96% (22/2303 cases) in the rivaroxaban group and 0.27% (9/3273 cases) in the LMWH group (p < 0.001). Only one patient treated with LMWH after TKA was diagnosed with symptomatic PE in this study. There was no significance difference in terms of safety between rivaroxaban and LMWH (p > 0.05) in terms of the incidence of bleeding events and TBL. However, in the TKA subgroup, TBL was significantly higher in the rivaroxaban group than in the LMWH group (915 ± 514 ml vs. 872 ± 487 ml, p = 0.030). With regards to transfusion rate, patients in the rivaroxaban group had a significantly higher need for blood transfusion than those in the LMWH group (OR 3.30,95% CI 2.88-3.78;p < 0.001). Subgroup analysis revealed that the transfusion rates in the THA and TKA sub-groups were both higher in the rivaroxaban group (14.8%, 14.2%) than those in the LMWH group (6.5%, 3.0%) (p < 0.001).
conclusionsFor patients following primary unilateral THA/TKA, LMWH is superior to rivaroxaban in terms of the prevention of symptomatic in-hospital DVT' and the control of TBL and transfusion rates. However, the efficacy of these drugs for controlling bleeding events was similar when compared between the two groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.